Risk stratification was according to DIPSS-plus system. 2 Screening for JAK2, CALR, MPL, ASXL1, TET2, EZH2, IDH1, IDH2 and spliceosome (SF3B1, U2AF1, SRSF2, ZRSR2) mutations was performed according to previously described methods. 6, 7 Statistical analyses considered clinical and laboratory data collected at the time of diagnosis or referral to the Mayo Clinic. Differences in the distribution of continuous variables between categories were analyzed by either Mann-Whitney or Kruskal-Wallis test. Patient groups with nominal variables were compared by Χ 2 test. Survival analysis was considered from the date of diagnosis or referral to date of death (uncensored) or, last contact (censored). Survival curves were prepared by the Kaplan-Meier method and compared by the log-rank test. The Cox proportional hazard regression model was used for multivariate survival analysis. Po0.05 was considered significant. The Stat View (SAS Institute, Minneapolis, MN, USA) statistical package was used for all calculations.
A total of 722 PMF patients (median age was 64, and 64% were males) were studied. Presenting clinical and laboratory details are outlined in Table 1 . Cytogenetic studies were available in 703 patients and included normal karyotype in 61% and normal or favorable abnormalities in 88%. 9 Other mutations that were concomitantly analyzed included ASXL1 (n = 480), SF3B1 (n = 415), U2AF1 (n = 457), SRSF2 (n = 474), TET2 (n = 180), EZH2 (n = 374), ZRSR2 (n = 180), IDH1 (n = 187) and IDH2 (n = 187); their respective frequencies were 38, 8, 16, 15, 18, 4, 11, 5 and 7%.
Patients were stratified according to the grade of anemia as mild (for hemoglobin level ⩾ 10 g/dl but below sex-adjusted normal value), moderate (for hemoglobin level between 8 g/dl and o10 g/dl) and severe (hemoglobin o8 g/dl or transfusion-dependent). At time of referral, 628 (87%) patients had anemia, of which 295 (47%) were mild, 98 (16%) moderate and 235 (37%) severe.
In univariate analysis, anemia was significantly associated with advanced age (Po0.0001), lower leukocyte count (Po0.0001), lower platelet count (Po0.0001), presence of circulating blasts (P = 0.0014), presence of constitutional symptoms (Po0.0001), driver mutational status (Po0.0001) and U2AF1 mutation (Po0.0001). On multivariate analysis, advanced age (P = 0.0002), lower platelet count (P = 0.03), the presence of constitutional symptoms (P = 0.04), absence of JAK2 mutation (P = 0.03), absence of CALR type 1/type 1-like mutation (P = 0.01) and presence of U2AF1 (Po0.0001) retained significance.
At a median follow-up of 3 years (range 0-28.1 years), 439 (61%) deaths were recorded. In univariate analysis, the presence of U2AF1 mutation is associated with inferior survival (Po 0.0001; Figure 1 ). However, significance was lost when analysis was adjusted for age and anemia (P = 0.24)
The current study confirms our previous observation regarding the association of mutant U2AF1 with anemia, 10 supporting its role in hematopoiesis 11 and in the pathogenesis of PMF-associated anemia. Our observation also supports the need to screen patients with PMF for U2AF1 mutations, in order to identify those who are at risk for the development of anemia, as well as those who might benefit from accordingly targeted therapy. Letter to the Editor
